1. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα
- Author
-
Lev Lichtenstein, Eran Maoz, Sophy Goren, Adva Levy-Barda, Eyal Shachar, Maya Aharoni Golan, Michal Navon, Maor H. Pauker, Baruch Ovadia, Natalia T. Freund, Arie Segal, Hadar Edelman-Klapper, Rami Eliakim, Joel Alter, Jacob E. Ollech, Hagar Banai-Eran, Keren M. Rabinowitz, Haim Ben Zvi, Revital Barkan, Michal Werbner, Idan Goren, Ariella Bar-Gil Shitrit, Yelena Broitman, Henit Yanai, Tsachi-Tsadok Perets, Yifat Snir, Noy Krugliak, Shomron Ben-Horin, Dani Cohen, Meital Gal-Tanamy, Adi Friedenberg, Irit Avni-Biron, Moshe Dessau, Iris Dotan, and Eran Zittan
- Subjects
Adult ,Male ,medicine.medical_specialty ,Booster dose ,Antibodies, Viral ,Gastroenterology ,Article ,Immunogenicity, Vaccine ,vaccine ,Internal medicine ,Adalimumab ,medicine ,Humans ,Prospective Studies ,Israel ,Prospective cohort study ,Adverse effect ,BNT162 Vaccine ,mRNA-BNT162b2 ,Crohn's disease ,Hepatology ,biology ,SARS-CoV-2 ,business.industry ,C-reactive protein ,COVID-19 ,serologic response ,Middle Aged ,Inflammatory Bowel Diseases ,medicine.disease ,Ulcerative colitis ,Infliximab ,Case-Control Studies ,biology.protein ,Female ,Tumor Necrosis Factor Inhibitors ,business ,medicine.drug - Abstract
Background Patients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor-necrosis-factor (TNF)α biologics are at high risk for vaccine preventable infections. Their ability to mount adequate vaccine responses is unclear. Aim To assess serologic responses to mRNA-COVID-19 vaccine, and safety profile, in patients with IBD stratified according to therapy, compared to healthy controls (HC). Methods Prospective, controlled, multi-center Israeli study. Subjects enrolled received two BNT162b2 (Pfizer/BioNTech) doses. Anti-spike antibodies levels and functional activity, anti-TNFα levels and adverse events (AEs) were detected longitudinaly. Results Overall 258 subjects: 185 IBD (67 treated with anti-TNFα, 118 non-anti-TNFα), and 73 HC. After the first vaccine dose all HC were seropositive, while ∼7% of patients with IBD, regardless of treatment, remained seronegative. After the second dose all subjects were seropositive, however anti-spike levels were significantly lower in anti-TNFα treated compared to non-anti-TNFα treated patients, and HC (both P, Graphical abstract
- Published
- 2022